SDC1 and Miyoshi myopathy: This model incorporates intravenous injection of proteasome inhibitor resistant MM.1S BzR cells and faithfully models the human pathology of relapsed/refractory MM with colonization of the bone marrow by CD138 + MM plasma cells and poor sensitivity to Btz therapy [17].